Providing Solutions for Drug Discovery Needs
Partnering with experts in relevant areas, FCDI strives to bring solutions using induced pluripotent stem (iPS) cell technology applications in drug discovery, drug safety and toxicity, drug responsiveness prediction and drug release assays. These partnerships empower customers to have a one-stop-shop for target identification and validation, assay development, and compound screening with choices from a broad range of specialized/proprietary assays in addition standard assays.
CRO Partners:
Axcelead Drug Discovery Partners is a market leading solution provider in the drug discovery space. Axcelead Drug Discovery Partners, Inc. will combine scientific excellence, world-class IP protection and state-of-the art GLP accredited facilities and capabilities to deliver integrated end-to-end early discovery.
Axxam S.p.A. is a privately owned iPRO (innovative Partner Research Organization) and discovery company located at the Science Park OpenZone in Bresso (Milan, Italy). The Company is a leading provider of discovery services for the entire life sciences industries including pharmaceuticals, crop protection, animal health, cosmetics and nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies, including assay development, compound management, HTS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need. For more information, please visit www.axxam.com.
PhenoVista Biosciences is a CRO based in San Diego, California that provides customized, imaging-based, phenotypic assay services to clients around the world. PhenoVista has an unmatched expertise in combining the latest quantitative imaging technologies and data-analysis capabilities to assist clients in designing and implementing high-throughput, high-content assays in myriad in vitro systems, including primary cells and iPSC-derived neurons in 2D, 3D, co-culture, and microfluidic systems. PhenoVista has built its strong reputation on providing high-quality data with a collaborative, adaptable nature of engagement to biopharmaceutical clients that range from start-ups to global organizations. For more information, please visit www.phenovista.com.
Platform Partners:
Nanion Technologies is a leading provider of innovative instrumentation for ion channel drug discovery and screening. Nanion’s team has developed four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cell monitoring and cardiotoxicity screening (CardioExcyte 96/FLEXcyte 96), for parallel bilayer recordings (Orbit family), and for parallel membrane transporter protein recordings (SURFE²R).
